Anti-TFAP2D antibody (70-82) (STJ71700)

SKU:
STJ71700-100

Shipping:
Free Shipping
Current Stock:
Host: Goat
Applications: Pep-ELISA
Reactivity: Human/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Goat polyclonal antibody anti-TFAP2D (70-82) is suitable for use in ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA
Purification: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Concentration: 0.5 mg/mL
Dilution Range: ELISA-antibody detection limit dilution 1:2000.
Storage Instruction: Store at-20°C on receipt and minimise freeze-thaw cycles.
Gene Symbol: TFAP2D
Gene ID: 83741
Uniprot ID: AP2D_HUMAN
Immunogen Region: 70-82
Accession Number: NP_758438.2
Immunogen Sequence: HHQSFHYEFQHSH
Function Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC.
Protein Name Transcription Factor Ap-2-Delta
Ap2-Delta
Activating Enhancer-Binding Protein 2-Delta
Transcription Factor Ap-2-Beta-Like 1
Database Links Reactome: R-HSA-8866904
Reactome: R-HSA-8866907
Cellular Localisation Nucleus
Alternative Antibody Names Anti-Transcription Factor Ap-2-Delta antibody
Anti-Ap2-Delta antibody
Anti-Activating Enhancer-Binding Protein 2-Delta antibody
Anti-Transcription Factor Ap-2-Beta-Like 1 antibody
Anti-TFAP2D antibody
Anti-TFAP2BL1 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance